Similar articles

• Multidrug resistance in human cancer.

  Goldstein LJ, Pastan I, Gottesman MM. Goldstein LJ, et al. Crit Rev Oncol Hematol. 1992;12(3):243-53. doi: 10.1016/1040-8428(92)90057-w. Crit Rev Oncol Hematol. 1992. PMID: 1353966 Review. No abstract available.
• Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

  Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP, Salmon SE. Dalton WS, et al. J Clin Oncol. 1989 Apr;7(4):415-24. doi: 10.1200/JCO.1989.7.4.415. J Clin Oncol. 1989. PMID: 2564428
• Multidrug resistance (MDR) genes in haematological malignancies.

  Nooter K, Sonneveld P. Nooter K, et al. Cytotechnology. 1993;12(1-3):213-30. doi: 10.1007/BF00744665. Cytotechnology. 1993. PMID: 7765326 Review.
• Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.

  Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP. Salmon SE, et al. Blood. 1991 Jul 1;78(1):44-50. Blood. 1991. PMID: 1676918 Clinical Trial.
• P-glycoprotein expression in bladder cancer.

  Park J, Shinohara N, Liebert M, Noto L, Flint A, Grossman HB. Park J, et al. J Urol. 1994 Jan;151(1):43-6. doi: 10.1016/s0022-5347(17)34868-1. J Urol. 1994. PMID: 7902877